Over-prescription of short-acting β₂-agonists remains a serious health concern in Kenya: results from the SABINA III study.

ABSTRACT:

Background

Despite a high asthma burden in Kenya, insights into asthma management practices, including prescription of short-acting β₂-agonists (SABAs), are lacking. Therefore, this study describes patient demographics, disease characteristics, and asthma treatment patterns in the Kenyan cohort of the SABA use IN Asthma (SABINA) III study.

Methods

Patients with asthma (aged ≥ 12 years) with medical records containing data for ≥ 12 months prior to the study visit from 19 sites across Kenya were included in this cross-sectional study and classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA] recommendations) and practice type (primary/specialist care). Data on severe exacerbation history, prescribed asthma treatmen

SUBMITTER: Chakaya J 

PROVIDER: S-EPMC10329295 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature